Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

NCT06299852 is registered in ClinicalTrials.gov with N.N. Petrov National Medical Research Center of Oncology as lead sponsor.

NCT NCT06299852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06299852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
Lead sponsor
N.N. Petrov National Medical Research Center of Oncology
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2022
Completion date
September 1, 2025
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive metastatic breast cancer, oligometastatic disease